Patient-Identified Most Bothersome Symptom in Patients With Chronic Migraine: An Analysis of PROMISE-2

被引：0

作者：

Lipton, R. B. ^{[1
]}

Dodick, D. W. ^{[2
]}

Ailani, J. ^{[3
]}

Winner, P. K. ^{[4
,5
,6
,7
]}

Hindiyeh, N. A. ^{[8
]}

Hirman, J. ^{[9
]}

Snapinn, S. ^{[10
]}

Mehta, L. ^{[10
]}

Cady, R. ^{[10
]}

机构：

[1] Albert Einstein Coll Med, Bronx, NY 10467 USA

[2] Mayo Clin, Scottsdale, AZ USA

[3] Georgetown Univ Hosp, Dept Neurol, Washington, DC 20007 USA

[4] Nova Southeastern Univ, Palm Beach Headache Ctr, W Palm Beach, FL USA

[5] Nova Southeastern Univ, Neurol Res Inst Palm Beach, W Palm Beach, FL USA

[6] Nova Southeastern Univ, Premiere Res Inst, W Palm Beach, FL USA

[7] Nova Southeastern Univ, Palm Beach Neurol, W Palm Beach, FL USA

[8] Stanford Univ, Sch Med, Stanford, CA 94305 USA

[9] Pacific Northwest Stat Consulting Inc, Woodinville, WA USA

[10] Lundbeck Seattle BioPharmaceut Inc, Bothell, WA USA

来源：

HEADACHE | 2020年 / 60卷

关键词：

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

引用

页码：117 / 118

页数：2

共 50 条

[11] Patient-perceived improvements in migraine and most bothersome symptom among patients treated with eptinezumab
Awad, S.
Rieckmann, A.
Lee, X. Ying
Boserup, L.
Regnier, S. A.
[J]. EUROPEAN JOURNAL OF NEUROLOGY, 2023, 30 : 373 - 373
[12] Eptinezumab Reduced the Frequency of Migraine Days in Patients With Chronic Migraine and Medication-Overuse Headache: Subgroup Analysis of PROMISE-2
Diener, H.
Marmura, M.
Hirman, J.
Mehta, L.
Brevig, T.
Brunner, E.
Cady, R.
[J]. HEADACHE, 2020, 60 : 107 - 107
[13] Eptinezumab Reduced the Frequency of Migraine Days in Patients with Chronic Migraine and Medication-Overuse Headache: Subgroup Analysis of PROMISE-2
Diener, H. -C.
Marmura, M.
Hirman, J.
Mehta, L.
Brevig, T.
Brunner, E.
Cady, R.
[J]. EUROPEAN JOURNAL OF NEUROLOGY, 2020, 27 : 155 - 155
[14] Eptinezumab Improved Patient-Reported Outcomes in Patients With Chronic Migraine and Medication-Overuse Headache: Subgroup Analysis of PROMISE-2
Diener, H.
Marmura, M.
Cowan, R. P.
Diamond, M.
Tepper, S. J.
Starling, A. J.
Hirman, J.
Mehta, L.
Sperling, B.
Brevig, T.
Brunner, E.
Cady, R.
[J]. HEADACHE, 2020, 60 : 106 - 107
[15] Migraine-Free Months in Patients with Episodic or Chronic Migraine Treated with Eptinezumab: Results from the PROMISE-1 and PROMISE-2 Trials
Winner, P. K.
McAllister, P.
Cady, R.
Snapinn, S.
Hirman, J.
Kassel, E.
[J]. HEADACHE, 2019, 59 : 162 - 162
[16] Eptinezumab for Migraine Prevention in Patients 50 Years or Older: A Subgroup Analysis of PROMISE-1 and PROMISE-2
Martin, V.
Tassorelli, C.
Ettrup, A.
Hirman, J.
Cady, R.
[J]. JOURNAL OF HEADACHE AND PAIN, 2021, 22 (SUPPL 1): : 105 - 106
[17] Eptinezumab for Migraine Prevention in Patients 50 Years or Older: A Subgroup Analysis of PROMISE-1 and PROMISE-2
Martin, V.
Tassorelli, C.
Ettrup, A.
Hirman, J.
Cady, R.
[J]. CEPHALALGIA, 2021, 41 (1_SUPPL) : 157 - 157
[18] Eptinezumab for migraine prevention in patients 50 years or older: A subgroup analysis of PROMISE-1 and PROMISE-2
Martin, V. T.
Tassorelli, C.
Ettrup, A.
Hirman, J.
Cady, R.
[J]. HEADACHE, 2021, 61 : 125 - 126
[19] Eptinezumab Reduced Acute Medication Use in Patients with Chronic Migraine and Medication-Overuse Headache: Subgroup Analysis of PROMISE-2
Marmura, M.
Diener, H. -C.
Hirman, J.
Cady, R.
Brevig, T.
Brunner, E.
Mehta, L.
[J]. EUROPEAN JOURNAL OF NEUROLOGY, 2020, 27 : 298 - 298
[20] Preventive Treatment With Eptinezumab in Patients With a Dual Diagnosis of Chronic Migraine and Medication- Overuse Headache: Subgroup Analysis of PROMISE-2
Marmura, Michael J.
Diener, Hans-Christoph
Cowan, Robert P.
Starling, Amaal J.
Hirman, Joe
Brevig, Thomas
Cady, Roger
[J]. NEUROLOGY, 2023, 100 (17)

← 1 2 3 4 5 →